Icahn drops Genzyme stock
Executive Summary
Carl Icahn has divested the 1.5 million shares of Genzyme he acquired in the third quarter of 2007. The Genzyme investment was no longer listed as part of Icahn Capital Management's portfolio by the end of 2007, according to SEC filings. The stock's value took a healthy bump when the management firm's third-quarter filing became public. Icahn's attention is focused on Genzyme's Cambridge, Mass., neighbor Biogen Idec, where he holds 8.3 million shares and is making a play to control the board at the annual meeting in May...